<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-041836</identifier>
<setSpec>1130-0108</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Hyperhomocysteinemia and methylenetetrahydrofolate reductase 677&amp;#8594;T and 1298A&amp;#8594; mutations in patients with inflammatory bowel disease</dc:title>
<dc:description xml:lang="en">Background: hyperhomocysteinemia has been recently describedin patients with inflammatory bowel disease (IBD), thatcould be related to the increased risk for thrombosis that exists inthis disease. The aim of this study was the assessment of hyperhomocysteinemiain patients with IBD and its relation among vitaminB12 and folate levels, and methylenetetrahydrofolate reductase(MTHFR) 677C&amp;#8594; T and 1298A&amp;#8594;C mutations.Patients and methods: fifty two consecutive patients withIBD were studied (29 women and 23 men); age: mean (standarddeviation 41.7 [11.9] years) and 186 controls with no differencein age and gender. Hyperhomocysteinemia was considered as homocysteinelevels higher than mean plus two standard deviationsof the control group (&amp;#8805; 13 &amp;micro;mol/l).Results: patients had an elevated prevalence of hyperhomocysteinemia(17.3 vs. 3.7%; p = 0.002) and lower folate (7.6[4.1] vs. 8.9 [3.7] ng/ml; p = 0.01) and B12 vitamin levels (499[287] vs. 603 [231] pg/ml; p = 0.003). Homocysteinemia washigher (14.3 [5.8] vs. 9.1 [3.9] &amp;micro;mol/l; p = 0.006) in 6 patients(11.5%) that had suffered thromboembolism. Frequency of MTHFR677C&amp;#8594;T (13.5 vs. 11.3%; p = 0.66) and 1298A&amp;#8594;C (7.8 vs.7.0%; p = 0.76) mutations was not increased in patients. Odds ratio(OR) for IBD in hyperhomocysteinemic patient was 5.51, 95%confidence interval (CI), 1.81-16.76; p = 0.002). Hyperhomocysteinemiawas negatively associated with feminine gender (OR0.08, 95% CI 0.01-0.49; p = 0.006) and folate levels (OR 0.04,95%CI: 0.007-0.20; p &lt; 0.001).Conclusions: hyperhomocysteinemia is associated with IBDand low folate levels, and could be involved in development ofthromboembolism. MTHFR 677C&amp;#8594;T and 1298A&amp;#8594;C mutationsare not related with the disease</dc:description>
<dc:creator>Gómez González, P</dc:creator>
<dc:creator>Gómez de la Cámara, A</dc:creator>
<dc:creator>Casis Herce, B</dc:creator>
<dc:creator>Sánchez Gómez, F</dc:creator>
<dc:creator>Sáenz-López Pérez, S</dc:creator>
<dc:creator>Martínez López, J</dc:creator>
<dc:creator>Martínez Prieto, M</dc:creator>
<dc:creator>Fernández-Miranda, C</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Fundamento: recientemente se ha descrito la existencia de hiperhomocisteinemia en la enfermedad inflamatoria intestinal(EII), que podría estar relacionada con el mayor riesgo de trombosisen esta enfermedad. El objetivo del estudio ha sido evaluar la hiperhomocisteinemia en los pacientes con EII y su relación con las concentraciones de vitamina B12 y folato séricos y con las mutacionesde la metilentetrahidrofolato reductasa (MTHFR)677C&amp;#8594;T y 1298A&amp;#8594;C.Pacientes y métodos: se estudiaron consecutivamente 52 pacientes con EII (29 mujeres y 23 varones; edad: media [desviación estándar] 41,7 [11,9] a&amp;ntilde;os) y 186 controles con edad y sexo similares. Se consider&amp;oacute; hiperhomocisteinemia cuando los valoresde homociste&amp;iacute;na eran superiores a la media m&amp;aacute;s dos desviacionesest&amp;aacute;ndar del grupo control (&amp;#8805; 13 &amp;micro;mol/l).Resultados: los pacientes presentaban una mayor prevalenciade hiperhomocisteinemia (17,3 frente a 3,7%; p = 0,002) yunos valores m&amp;aacute;s bajos de folato (7,6 [4,1] frente a 8,9 [3,7]ng/ml; p = 0,01) y de vitamina B12 (499 [287] frente a 603 [231]pg/ml; p = 0,003). En 6 pacientes (11,5%) que hab&amp;iacute;an padecidoepisodios tromboemb&amp;oacute;licos la homocisteinemia era m&amp;aacute;s elevada(14,3 [5,8] frente a 9,1 [3,9] &amp;micro;mol/l; p = 0,006). La frecuenciade las mutaciones MTHFR 677C&amp;#8594;T (13,5% frente a 11,3%; p= 0,66) y de la 1298A&amp;#8594;C (7,8 frente a 7,0%; p=0,76) no fuemayor en los pacientes. La odds ratio (OR) de EII en los pacienteshiperhomocistein&amp;eacute;micos fue 5,51, intervalo de confianza [IC]del 95%: 1,81-16,76; (p = 0,002). La hiperhomocisteinemia seasoci&amp;oacute; negativamente con el sexo femenino (OR 0,08, IC del95%, 0,01-0,49; p = 0,006) y con los valores de folato (OR0,04,IC del 95%: 0,007-0,20; p &lt; 0,001).Conclusiones: la hiperhomocisteinemia se asocia a la EII y alas concentraciones bajas de folato, y puede estar implicada en eldesarrollo de tromboembolia. Las mutaciones MTHFR 677C&amp;#8594; Ty 1298A&amp;#8594; C no se relacionan con la enfermedad</dc:description>
<dc:source>Rev Esp Enferm Dig;97(7): 497-504, jul. 2005. tab</dc:source>
<dc:identifier>ibc-041836</dc:identifier>
<dc:title xml:lang="es">Hiperhomocisteinemia y mutaciones de la metilentetrahidrofolato reductasa 677C&amp;#8594; T y 1298A&amp;#8594; C en pacientes con enfermedad inflamatoria intestinal</dc:title>
<dc:subject>^d9346</dc:subject>
<dc:subject>^d28623</dc:subject>
<dc:subject>^d27830</dc:subject>
<dc:subject>^d14308^s22027</dc:subject>
<dc:subject>^d33775^s22012</dc:subject>
<dc:subject>^d23695^s22033</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23695^s22012</dc:subject>
<dc:subject>^d28584</dc:subject>
<dc:subject>^d24584</dc:subject>
<dc:subject>^d33775^s22080</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d6866^s22062</dc:subject>
<dc:subject>^d23695^s22062</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d38206^s22033</dc:subject>
<dc:subject>^d33775^s22016</dc:subject>
<dc:subject>^d5629^s22062</dc:subject>
<dc:type>article</dc:type>
<dc:date>200507</dc:date>
</metadata>
</record>
</ibecs-document>
